Forsta AP Fonden Grows Holdings in Catalent, Inc. (NYSE:CTLT)

Forsta AP Fonden increased its position in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 106.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,900 shares of the company's stock after acquiring an additional 19,000 shares during the quarter. Forsta AP Fonden's holdings in Catalent were worth $2,235,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalent in the second quarter worth $42,000. Longfellow Investment Management Co. LLC lifted its holdings in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock worth $55,000 after purchasing an additional 305 shares during the last quarter. GAMMA Investing LLC boosted its position in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after purchasing an additional 212 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its holdings in Catalent by 1,400.0% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,500 shares of the company's stock valued at $91,000 after purchasing an additional 1,400 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Catalent by 456.6% in the second quarter. Federated Hermes Inc. now owns 2,833 shares of the company's stock worth $159,000 after buying an additional 2,324 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Ricky Hopson sold 662 shares of the firm's stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the sale, the insider now owns 29,974 shares of the company's stock, valued at $1,785,251.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Ricky Hopson sold 662 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares of the company's stock, valued at $1,785,251.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Mcerlane sold 1,994 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company's stock, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,642 shares of company stock valued at $217,860 in the last 90 days. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CTLT shares. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Robert W. Baird reiterated a "neutral" rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. StockNews.com assumed coverage on shares of Catalent in a research note on Saturday, October 12th. They issued a "hold" rating on the stock. William Blair reiterated a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Finally, Baird R W lowered shares of Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. Nine research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $59.83.

Catalent Price Performance

Shares of CTLT stock traded down $0.37 during mid-day trading on Thursday, reaching $58.60. The company's stock had a trading volume of 1,172,437 shares, compared to its average volume of 2,042,486. The firm's 50-day moving average is $60.08 and its two-hundred day moving average is $57.93. The company has a market cap of $10.61 billion, a P/E ratio of -9.65, a PEG ratio of 2.14 and a beta of 1.15. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52.

Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The business had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. On average, research analysts predict that Catalent, Inc. will post 0.95 earnings per share for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.